SAGE Therapeutics stock changed hands for USD 8.50 per share

SAGE Therapeutics stock changed hands at USD 8.50 per share when Supernus completed its acquisition of the biotechnology company on July 31, 2025, according to Investing.com. The transaction shifted Sage Therapeutics from an independently traded Nasdaq company into Supernus's neuropsychiatry portfolio.

Acquisition fixes the valuation anchor

The USD 8.50 per-share consideration is the clearest valuation reference for Sage Therapeutics after the transaction. It also provides a concrete comparison with the company's operating results, because the acquisition value was set before the business reached positive cash flow.

Supernus described the Sage acquisition as part of its neuropsychiatry expansion in a September 2026 earnings-call report carried by Yahoo Finance. The deal brought Zurzuvae into Supernus's product portfolio and connected Sage's central nervous system pipeline with a larger commercial platform.

Revenue stayed below consensus

In Q1 2025, Sage Therapeutics reported revenue of USD 14.06 million against a USD 14.14 million consensus estimate, a shortfall of USD 0.08 million. The figure shows why the acquisition thesis depended on commercial expansion rather than on the quarter's revenue alone.

The same Q1 2025 summary showed a net loss of USD 62.2 million, compared with USD 95.8 million in Q4 2024. The loss therefore narrowed by USD 33.6 million quarter over quarter, while XERZUVEY shipments increased 22 percent over the same period.

Pipeline value moves to Supernus

Sage Therapeutics focused on central nervous system treatments, including Zurzuvae for postpartum depression and development programs such as dalzanemdor. The Q1 2025 update also linked the company's long-term plan to becoming cash-flow positive with XERZUVEY by the end of 2026, making product uptake the key operating comparison against the acquisition price.

Stock story ends with the transaction

SAGE Therapeutics stock is best assessed through the USD 8.50 per-share acquisition value dated July 31, 2025, while the Q1 2025 figures explain the commercial and cash-flow expectations transferred to Supernus.